Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
Laura Burns(Boston University), Ümit Tapan(Boston University), Marjory Charlot(University of North Carolina at Chapel Hill), Melina E. Marmarelis(University of Pennsylvania), Hirva Mamdani(Wayne State University), Sarah B. Goldberg(Yale University), Katherine A. Scilla(University of Maryland, Baltimore), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Heather A. Wakelee(Palo Alto Institute), Chih–Yuan Hsu(Vanderbilt University Medical Center), Mary J. Fidler, Daniel B. Costa(Beth Israel Deaconess Medical Center), Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Stephen V. Liu(Georgetown University), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Sonam Puri(University of Utah), Leora Horn(Vanderbilt University), Solange Peters(University Hospital of Lausanne), Aaron S. Mansfield(Mayo Clinic), Fred R. Hirsch(Tisch Hospital), Jennifer G. Whisenant(Vanderbilt-Ingram Cancer Center), Matthew Puc(Virtua Health), Balázs Halmos(Montefiore Medical Center), Lawrence Feldman(University of Illinois Chicago), Marina Chiara Garassino(University of Chicago), Nahida Islam(University of Massachusetts Chan Medical School), Carolyn J. Presley(The Ohio State University), Hina Khan, Julie R. Brahmer(Johns Hopkins University)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k